United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $543.32, for a total value of $5,161,540.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at $176,276,370.76. This represents a 2.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Price Performance

United Therapeutics stock opened at $553.88 on Wednesday. The stock’s fifty day moving average price is $514.68 and its two-hundred day moving average price is $539.60. United Therapeutics Corporation has a one year low of $409.07 and a one year high of $609.35. The firm has a market cap of $23.76 billion, a PE ratio of 19.82, a price-to-earnings-growth ratio of 3.89 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $6.41 EPS. Sell-side analysts expect that United Therapeutics Corporation will post 26.40 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Toth Financial Advisory Corp increased its stake in shares of United Therapeutics by 2,400.0% in the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 48 shares during the period. Fiduciary Financial Advisors bought a new position in United Therapeutics in the 2nd quarter valued at approximately $30,000. Caitlin John LLC acquired a new stake in United Therapeutics during the 2nd quarter worth approximately $37,000. International Assets Investment Management LLC boosted its position in United Therapeutics by 426.7% during the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after buying an additional 64 shares during the period. Finally, Keating Financial Advisory Services Inc. bought a new stake in United Therapeutics during the 2nd quarter worth approximately $81,000. Institutional investors own 94.08% of the company’s stock.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analyst optimism supports the stock. Leerink Partners raised its price target to $725 from $685 while maintaining an “outperform” rating. The broader analyst consensus is a “Moderate Buy,” with an average target of approximately $650. Recent coverage also highlights United Therapeutics as a potentially underappreciated, highly profitable biotechnology company. Analysts Are Bullish on Top Healthcare Stocks United Therapeutics Profit Machine
• Positive Sentiment: FDA clearance advances the SUMMIT trial. The FDA authorized United Therapeutics to proceed with a clinical study of treprostinil inhalation powder, or SMI, in patients with pulmonary hypertension associated with COPD. The trial could expand the company’s addressable market beyond its established pulmonary arterial hypertension business. FDA Clears SUMMIT Study
• Positive Sentiment: Organ-manufacturing capacity is expanding. United Therapeutics opened its third designated pathogen-free xenograft production facility in Houston, strengthening its ability to develop and manufacture genetically modified organs for transplantation. The investment reinforces the company’s longer-term organ-manufacturing strategy. Third Xenograft Production Facility
• Neutral Sentiment: Insider selling adds a modest cautionary signal. CEO Martine Rothblatt sold 9,500 shares in each of two reported transactions, while other executives also sold shares under trading plans. Rothblatt still retains a substantial stake, so the transactions may reflect scheduled diversification rather than a change in business outlook.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $368.00 price target on shares of United Therapeutics in a research note on Thursday, October 15th. Raymond James Financial reissued an “outperform” rating and issued a $717.00 target price on shares of United Therapeutics in a report on Tuesday. Morgan Stanley raised their target price on shares of United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Cantor Fitzgerald restated an “overweight” rating on shares of United Therapeutics in a research report on Thursday, October 1st. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $728.00 price target on shares of United Therapeutics in a report on Wednesday, October 14th. Twelve investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $651.21.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.